Ultrastructural localization of advanced glycation end products and β2-microglobulin in dialysis amyloidosis

Journal of Nephrology

Volumn 13, Issue 2, 2000, Pages 129-136

  Brancaccio, Diego ^a,d   Gallieni, Maurizio ^a   Niwa, Toshimitsu ^b   Braidotti, Paola ^c   Coggi, Guido ^c  

^a SAN PAOLO HOSPITAL   (Italy)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF MILAN   (Italy)

^d Ospedale San Paolo   (Italy)

Author keywords

2 Microglobulin; Advanced glycation end products; Dialysis related amyloidosis; Imidazolone; Immunoelectron microscopy; N( ) carboxymethyl lysine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BETA 2 MICROGLOBULIN; IMIDAZOLE DERIVATIVE;

AMYLOIDOSIS; ARTICLE; CARPAL TUNNEL SYNDROME; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOREACTIVITY; LYSOSOME; MUSCLE FIBRIL; PROTEIN LOCALIZATION; SYNOVIUM;

AMYLOIDOSIS; ANIMALS; BETA 2-MICROGLOBULIN; CARPAL TUNNEL SYNDROME; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE; MICROSCOPY, ELECTRON; RABBITS; RENAL DIALYSIS; SYNOVIAL MEMBRANE; TENDONS;

EID: 0034112055     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Gejyo F, Brancaccio D. Beta-2-microglobulin: a possible new uremic toxin? Int J Artif Organs 1988; 11: 3-5.
2. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Schmid K. A new form of amyloid protein associated with chronic hemodialysis was identified as ß2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-6.
3. Gorevich PD, Casey TT, Stone WJ, Di Raimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985; 76: 2425-9.
4. Aruga E, Ozasa H, Terakawa S, Ota K. Macromolecules that are colocalized with deposits of ß2-microglobulin in hemodialysis associated amyloidosis. Lab Invest 1993; 69: 223-30.
5. Homma N, Gejyo F, Isemura M, Arakawa M. ß2-microglobulin binding to collagen: An amyloidogenic factor in chronic hemodialysis. In: Isobe T, Araki S, Uchino F, Kito S, Tsubura E, eds. Amyloid and Amyloidosis. New York: Plenum 1988; 623-7.
6. Argilés A, Mourad G, Axelrud-Cavadore C, Watrin A, Mion C, Cavadore JC. High molecular weight proteins in haemodialysis-associated amyloidosis. Clin Sci 1989; 76: 547-52.
7. Gouin-Charnet A, Mourad G, Argilés A. α2-Macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. Biochem Biophys Res Commun 1997; 231: 48-51.
8. Brancaccio D, Ghiggeri GM, Braidotti P, Garberi A, Gallieni M, Bellotti V, Zoni U, Gusmano R, Coggi G. Deposition of kappa and lambda light chains in amyloid fialments of dialysis-related amyloidosis. J Am Soc Nephrol 1995; 6: 1262-70.
9. Miyata T, Oda O, Inagi R, Lida Y, Araki N, Yamada N. ß2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-52.
10. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda H, Seo H. Involvement of ß2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521-8.
11. Miyata T, Taneda S, Kawai R. Identification of pentosidine as a native structure for advanced glycation end products in ß2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-58.
12. Niwa T, Miyazaki S, Katsuzaki T, Tatemichi N, Takei Y, Miyazaki T, Morita T, Hirasawa Y. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 1995; 48: 771-8.
13. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y. Modification of ß2-microglobulin with advanced glycation end products as observed in dialysis-related amyloidosis by 3-deoxyglucosone accumulating in uremic serum. Kidney Int 1996; 49: 861-7.
14. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid ß2-microglobulin is modified with Nε-carboxymethyl-lysine in dialysis-related amyloidosis. Kidney Int 1996; 50: 1303-9.
15. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y. Amyloid ß2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187-94.
16. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, Araki N. Structures of advanced glycation end products and their role in pathophysiological states. In: Maeda K and Shinzato T, eds. Dialysis-Related Amyloidosis. Contrib Nephrol. Basel: Karger, 1995; 112: 32-41.
17. Shin DB, Hayase F, Kato H. Polymerization of proteins caused by reaction with sugars and the formation of 3-deoxyglucosone under physiological conditions. Agr Biol Chem 1988; 52: 1451-8.
18. Kato H, Cho RK, Oitani A, Hayase F. Responsibility of 3-deoxyglucosone for the glucose-induced polymerization of proteins. Agr Biol Chem 1987; 51: 683-9.
19. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. Nε-carboxymethyl-lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-8.
20. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380-4.
21. Nakamura K, Hasegawa T, Fukunaga Y, Ienaga K. Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of α-N-acetyl-L-lisyne with D-glucose. J Chem Soc Chem Commun 1992; 14: 992-4.
22. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 1989; 263: 3758-64.
23. Konishi Y, Hayase F, Kato H. Novel imidazolone compound formed by the advanced Maillard reaction of 3-deoxyglucosone and arginine residues in proteins. Biosci Biotech Biochem 1994; 58: 1953-5.
24. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsuu A, Maeda K, Ohara M, Tomiyama S, Niimura K. Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic serum. Nephron 1995; 69: 438-43.
25. Monta T, Suzuki M, Kamimura A, Hirasawa Y. Amyloidosis of a possible new type in patients receiving long-term hemodialysis. Arch Pathol Lab Med 1985; 109: 1029-32.
26. Depierreux M, Goldman M, Fayt I, Richard C, Quintin J, Dhaene M, Van Herweghem JL. Osteoarticular amyloidosis associated with haemodialysis: an immunoultrastructural study. J Clin Pathol 1988; 41: 158-62.
27. Coggi G, Maiorano E, Braidotti P, Dell'Orto P, Viale G. Beta-2-microglobulin amyloidosis in synovial membranes: histopathology, immunocytochemistry and electron microscopy. In: Gejyo F, Brancaccio D, Bardin T, eds. Dialysis Amyloidosis. Milano: Wichtig Editore, 1989; 57-78.
28. Argilés A, Mourad G, Kerr PG, Garcia M, Collins B, Demaille JG. Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant 1994; 9: 662-7.
29. Barland P, Novikoff AB, Hammerman D. Electron microscopy of the synovial membrane. J Cell Biol 1962; 14: 207-16.
30. Gejyo F, Maruyama H, Teramura T, Kazama J, Ei I, Arakawa M. Role of macrophages in ß2-microglobulin-related amyloidosis. In: Maeda K and Shinzato T, eds. Dialysis-Related Amyloidosis. Contrib Nephrol. Basel: Karger, 1995; 112: 97-104.
31. Nakagawa S. Ultrastructural investigations of amyloidosis: Pathogenesis of systemic amyloidosis. Appl Pathol 1984; 2: 328-40.
32. Lie JT. Pathology of amyloidosis and amyloid heart disease. Appl Pathol 1984; 2: 341-56.
33. Theaker JM, Raine AEG, Rainey AJ, Heryet A, Clark A, Oliver DO. Systemic amyloidosis of ß2-microglobulin type: a complication of long-term dialysis. J Clin Pathol 1987; 40: 1247-51.
34. Kumano K, Nanbu M, Kusakari S, Sakai T. Beta 2-microglobulin synthesis of mononuclear cells in chronic dialysis patients. Int J Artif Organs 1992; 15: 401-7.
35. Garcìa-Garcìa M, Garcìa-Valero J, Gouin-Charnet A, Mourad G, Chammas M, Durfort M, Argilés A. Impaired lysosomial processing of ß2-microglobulin (ß2-m) by infiltrating macrophages in dialysis amyloidosis (abstract). J Am Soc Nephrol 1996; 7: 1479.
36. Vlassara H, Brownlee M, Manogue KR, Cerami A. Cachectin/TNF and IL-1 induced by glucose-modified proteins. Science 1988; 240: 156-7.
37. Yui S, Sasaki T, Araki N, Horiuchi S, Yamasaki M. Induction of macrophage growth by advenced glycation end products of the Maillard reaction. J Immunol 1994; 152: 1943-9.
38. Doi T, Vlassara H, Kirstein M, Yamada Y, Stiker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 2873-7.
39. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, Schmidt AM. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98: 1088-94.
40. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Van SD, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM. N-epsilon-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.
41. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-80.
42. Ling X, Sakashita N, Tayeka M, Nagai R, Horiuchi S, Takahashi K. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest 1998; 78: 1591-606.
43. Odetti P, Forgarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-9.
44. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-206.
45. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi V, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-67.
46. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus M, Braatz JA, Owen AST. Interaction between ß2-microglobulin and advanced glycation end products in the development of dialysis related amyloidosis. Kidney Int 1997; 51: 1514-9.